Mohammad Majdi

Mohammad Majdi

Auto-generated profile, based on publicly available information

Mohammad Majdi

Miami University, Department of Chemical, Paper, and Biomedical Engineering, Oxford, OH, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2026 in Metabolic Engineering
Verified
Journal Article
Open access
ZAZachary N. Abrahms
Zachary N. Abrahms
MMMohammad Majdi
Mohammad Majdi
SMSiena M. Madsen
Siena M. Madsen
CMChloe J. Morton
Chloe J. Morton
ASAbhishek Kumar Sen
Abhishek Kumar Sen
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones
Stable, high-level biosynthesis of complex natural products requires precise control of heterologous pathway expression, yet transcriptional architectures optimized on plasmids often fail when transferred to the chromosome. Here, we present ePathIntegrate, a genome-centric pathway engineering strategy that leverages CRISPR-associated transposases (CASTs) to integrate and rebalance multigene metabolic pathways in Escherichia coli. Direct genomic transfer of plasmid-optimized psilocybin and N,N-dimethyltryptamine (DMT) pathways resulted in a loss of productivity, driven by context-dependent promoter behavior. To address this, we developed and characterized a library of mutant T7 promoters that restore mid-range transcriptional control on the genome. Applying ePathIntegrate enabled re-optimization of both pathways, yielding genome-encoded strains that achieve 1.88 g/L psilocybin and 1.62 g/L DMT in fed-batch bioreactors. Whole-genome sequencing of CAST-mediated strains further revealed (i) precise on-target integration, (ii) some off-target pathway integrations, and (iii) small mutations in a subset of strains, highlighting both the power and limitations of CAST-mediated strain engineering.